8-K: Akebia Amends Medice Vafseo License for Drug Supply

Akebia Therapeutics and Medice amend their Vafseo license agreement, with Akebia now supplying drug substance and Medice gaining manufacturing rights.

Summary

• Akebia Therapeutics, Inc. (Akebia) and MEDICE Arzneimittel Putter GmbH & Co. KG (Medice) entered into Amendment #1 to their License Agreement on November 12, 2025.
• The original License Agreement, dated May 24, 2023, granted Medice exclusive rights to develop and commercialize Vafseo for anemia in chronic kidney disease patients in Europe and other countries.
• Under the amendment, Akebia will supply vadadustat drug substance (Drug Substance) to Medice.
• Medice has been granted the right to manufacture Vafseo tablets using the Drug Substance supplied by Akebia.
• Any know-how or patent rights arising from Medice's manufacturing of Vafseo tablets will be owned by Akebia.

Sentiment

Score: 6

Explanation: The amendment is a positive operational clarification, ensuring Akebia's continued role in the supply chain and protecting its intellectual property, without introducing significant new risks or negative financial implications.

Positives

• Akebia maintains ownership of any new know-how or patent rights developed by Medice during the manufacturing of Vafseo tablets, protecting its intellectual property.
• The agreement clarifies the supply chain for Vafseo, with Akebia providing the core drug substance, potentially ensuring consistent revenue from this supply.

Negatives

• Medice gaining manufacturing rights could potentially reduce Akebia's direct manufacturing involvement or future revenue opportunities related to tablet production, though Akebia still supplies the drug substance.

Risks

• Potential for supply chain disruptions if Akebia faces challenges in providing the vadadustat drug substance to Medice.
• Quality control risks associated with Medice's manufacturing of Vafseo tablets, although Akebia retains IP ownership.
• Potential for disputes regarding the scope or ownership of know-how and patent rights arising from Medice's manufacturing activities.

Future Outlook

Akebia expects to file a copy of Amendment #1 to the License Agreement as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2025.

Industry Context

This amendment reflects ongoing operational adjustments common in pharmaceutical licensing and supply agreements, particularly for products like Vafseo (vadadustat) targeting chronic conditions such as anemia in chronic kidney disease. Such agreements often evolve to optimize manufacturing and supply logistics as products mature in their respective markets.

Stakeholder Impact

• Shareholders: The amendment clarifies operational aspects of a key product's supply and manufacturing, potentially reducing uncertainty and protecting intellectual property, which is generally positive for long-term value.

Next Steps

• Akebia Therapeutics, Inc. expects to file a copy of Amendment #1 to the License Agreement as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2025.

Key Dates

Recommendation

This filing details an operational amendment to an existing license agreement, primarily concerning the supply of drug substance and manufacturing rights. It does not introduce new revenue streams, significant financial metrics, or material changes to the company's strategic direction or risk profile that would warrant a change in investment recommendation. It's a routine business update that clarifies responsibilities within an established partnership.

Keywords

Akebia Therapeutics, Medice, Vafseo, vadadustat, License Agreement, Drug Substance, manufacturing rights, chronic kidney disease, anemia, pharmaceuticals, biotechnology